Interleukin-8, a promising predictor for prognosis of pancreatic cancer

Table 1 Clinical data of patients subjected to enzyme-linked immunosorbent assay analysis for serum interleukin-8

Groups	Sex		Age (yr)
	Male	Female	Range	Median
PDC	13	14	45-80	58
CP	13	2	9-58	40
AP	3	5	37-73	51
DA	3	5	47-65	58
GC	1	2	47-55	53
CRC	3	1	48-68	63
HCC	1	1	55-72	63.5

PDC: Pancreatic ductal carcinoma; CP: Chronic pancreatitis; AP: Acute pancreatitis; DA: Duodenal adenocarcinoma; GC: Gastric carcinoma; CRC: Colorectal carcinoma; HCC: Hepatocellular carcinoma.

Table 2 Background information of cell lines for interleukin-8 detection

Cell lines	Cell origin	Number in cell line library
BxPC3	Primary adenocarcinoma	CRL-1687 (ATCC)
CFPAC-1	Liver metastasis from adenocarcinoma	CRL-1918 (ATCC)
SW1990	Spleen metastasis from adenocarcinoma	CRL-2172 (ATCC)
Patu 8988s	Liver metastasis from adenocarcinoma	ACC 204 (DSMZ)

ATCC: American Type Culture Collection; DSMZ: German Collection of Microorganisms and Cell Cultures.

Table 3 Interleukin-8 and CXCR1 expression in pancreatic cancer, matched para-cancer tissue and chronic pancreatitis

	Pancreatic cancerdifferentiation			Matched para-cancer tissue	Chronic pancreatitis
	Well	Moderate	Poor
IL-8
+	5	33	7	21	0
-	11	22	3	60	5
CXCR1
+	10	35	8	10	1
-	6	20	2	71	4

IL-8: Interleukin-8.

Table 4 Interleukin-8 concentration in the supernatant of pancreatic cancer cell lines

Cell line	IL-8 concentration (ng/mL)
BxPC3	81.38
CFPAC-1	3.906
SW1990	> 500
Patu 8988s	498.9

SW1990 and Patu8988 originated from metastatic sites showed much higher levels of interleukin-8 (IL-8) than BxPC3 and CFPAC-1.